Last reviewed · How we verify
BPA prophylaxis
BPA prophylaxis prevents breakthrough polyomavirus-associated nephropathy (BPA) in immunocompromised patients, likely through antiviral or immunomodulatory mechanisms.
BPA prophylaxis prevents breakthrough polyomavirus-associated nephropathy (BPA) in immunocompromised patients, likely through antiviral or immunomodulatory mechanisms. Used for Prophylaxis of breakthrough polyomavirus-associated nephropathy in immunocompromised patients.
At a glance
| Generic name | BPA prophylaxis |
|---|---|
| Sponsor | Genzyme, a Sanofi Company |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | Phase 3 |
Mechanism of action
BPA (breakthrough polyomavirus-associated nephropathy) is a serious complication in transplant recipients. This prophylactic approach aims to prevent polyomavirus replication and associated kidney disease in high-risk immunocompromised populations. The exact mechanism may involve viral suppression or immune reconstitution strategies.
Approved indications
- Prophylaxis of breakthrough polyomavirus-associated nephropathy in immunocompromised patients
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B (PHASE3)
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (PHASE3)
- Low Dose Aspirin Alerts in High-Risk Pregnancies (NA)
- A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab (PHASE4)
- Life Expectancy-informed Colorectal Cancer Screening (NA)
- Impact of a Simple Automated Best Practice Alert (BPA) on Quantity and Quality of In-hospital Antibiotic Use in a Tertiary and Three Secondary Hospitals (NA)
- Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation With an Electronic Clinical Decision Support Tool (NA)
- A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPA prophylaxis CI brief — competitive landscape report
- BPA prophylaxis updates RSS · CI watch RSS
- Genzyme, a Sanofi Company portfolio CI